Want to see AU:BP8 full AI Analyst Report?
BP8 Stock Chart & Stats
AU$0.01
AU$0.00(0.00%)
At close: 4:00 PM EDT
AU$0.01
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.06 - AU$0.07
Previous CloseN/A
Volume0.00
Average Volume (3M)N/A
Market Cap
AU$4.71M
Enterprise ValueAU$3.55M
Total Cash (Recent Filing)AU$598.60K
Total Debt (Recent Filing)AU$577.48K
Price to Earnings (P/E)―
Beta-0.31
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding2,353,484,600
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.78
Price to Sales (P/S)3.20
P/FCF Ratio-1.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue ReboundA sustained multi-year revenue rebound demonstrates growing market traction and demand for the company's products. That top-line improvement provides a necessary base to leverage fixed costs and invest in commercialization or R&D, increasing the odds of eventual margin recovery if cost structure is controlled.
Low Reported Debt (2025)A very low reported debt position reduces fixed financing obligations and interest risk, preserving cash flexibility. Over the medium term this lowers insolvency pressure and gives management optionality for funding growth or navigating setbacks without heavy scheduled debt service.
Narrowing Free Cash Flow LossProgress toward smaller free cash flow deficits indicates the business is trending toward better cash discipline or higher operational leverage. If the trend continues, funding needs and dilution pressure lessen, improving the sustainability of operations over the next several quarters.
Bears Say
Recurring LossesPersistent operating and net losses erode internal capital, delay reinvestment ability, and require repeated external funding. Over a multi-quarter horizon this weakens capacity to scale, increases financing dependency, and elevates execution risk for commercial or development initiatives.
Negative Shareholder EquityNegative equity reflects cumulative losses and limits balance-sheet flexibility, reducing leverage capacity and making access to debt or favorable terms harder. Structurally it heightens solvency concerns and constrains strategic options like acquisitions or large capital projects.
Weak Cash GenerationOngoing negative operating and free cash flow means core operations do not self-fund and necessitate external capital. Over months this raises liquidity and dilution risk, can limit R&D or commercial investment, and makes long-term execution dependent on financing availability.
Stemcell United Ltd. News
BP8 FAQ
What was Stemcell United Ltd.’s price range in the past 12 months?
Stemcell United Ltd. lowest share price was AU$0.06 and its highest was AU$0.07 in the past 12 months.
What is Stemcell United Ltd.’s market cap?
Stemcell United Ltd.’s market cap is AU$4.71M.
When is Stemcell United Ltd.’s upcoming earnings report date?
Stemcell United Ltd.’s upcoming earnings report date is Aug 28, 2026 which is in 21 days.
How were Stemcell United Ltd.’s earnings last quarter?
Stemcell United Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.001.
Is Stemcell United Ltd. overvalued?
According to Wall Street analysts Stemcell United Ltd.’s price is currently Overvalued.
Does Stemcell United Ltd. pay dividends?
Stemcell United Ltd. does not currently pay dividends.
What is Stemcell United Ltd.’s EPS estimate?
Stemcell United Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Stemcell United Ltd. have?
Stemcell United Ltd. has 2,353,484,600 shares outstanding.
What happened to Stemcell United Ltd.’s price movement after its last earnings report?
Stemcell United Ltd. reported an EPS of -AU$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Stemcell United Ltd.?
Currently, no hedge funds are holding shares in AU:BP8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stemcell United Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:BP8 Sentiment 80%
Sector Average 63%
Sector Average 63%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
258.27%
Trailing 12-Months
Company Description
Stemcell United Ltd.
BPH Global Ltd, along with its associated entities, specializes in the procurement, production, promotion, and sale of traditional medicinal items. Its operational reach spans Australia, Singapore, China, and the broader Southeast Asian market. The company's diverse product range features both unprocessed and refined bird's nest offerings, alongside marine botanicals like Caulerpa Lentillifera (sea grapes) and various seaweeds. These products are utilized across multiple industries, including food, nutrition, healthcare, dietary supplements, cosmetics, and personal care. Headquartered in Melbourne, Australia, the company was founded in 1984 and transitioned to its current name, BPH Global Ltd, in June 2023, having previously been known as Stemcell United Limited.
Cynata Therapeutics Limited
―
Living Cell Technologies
―
Mesoblast Limited
―
Orthocell Ltd
―
Regeneus Ltd.
―